ESRX 79.50 Express Scripts $ESRX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
ESRX 79.50 Express Scripts $ESRX Hit a 52 week high of 79.53 Closing the day 09:45 at 79.50 +0.03 +0.04% With a day low of 79.07 and a total volume of 315,777.

ESRX Recent Posts: http://investorshangout.com/Express-Scripts-H...SRX-54047/

ESRX Express Scripts Recent Headline News

Jim Cramer's 'Mad Money' Recap: How You Can Profit From My Mistakes
at The Street - Wed Nov 19, 6:00PM CST
Even Cramer gets them wrong once in a while and he wants you to see, and avoid, the errors of his ways.
SBUX: 78.21 (+0.39), UA: 70.26 (-0.22), AMZN: 329.15 (+2.61), ESRX: 79.57 (+0.10), BBBY: 73.09 (+1.70), SNA: 135.42 (-0.36), DPZ: 93.05 (+1.64), WAG: 67.79 (unch), CL: 68.18 (-0.11)

Cramer's Mad Money - I Didn't Have Enough Confidence In Bed Bath & Beyond (11/19/14)
SA Editor Miriam Metzinger - Seeking Alpha - Thu Nov 20, 5:07AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday November 19. I Didn't Have Enough Confidence in Bed, Bath & Beyond (NASDAQ: BBBY ) . Other stocks mentioned: National Oilwell Varco (NYSE: NOV ),...
SBUX: 78.21 (+0.39), CBI: 55.02 (+0.62), NOV: 72.48 (+0.99), UA: 70.26 (-0.22), BBBY: 73.09 (+1.70), ESRX: 79.57 (+0.10), DPZ: 93.05 (+1.64), TKR: 42.41 (-0.04), WAG: 67.79 (unch), CL: 68.18 (-0.11)

11 Stocks Warren Buffett Loves in 2014
at The Street - Wed Nov 19, 7:28AM CST
Here's a look at 11 stocks Buffett's Berkshire Hathaway bought in the most recently reported quarter.
CHTR: 158.87 (+0.24), WMT: 84.48 (-0.51), PCP: 230.81 (-2.08), SU: 34.75 (+0.65), ESRX: 79.57 (+0.10), V: 250.65 (+0.79), IBM: 160.09 (-1.34), DTV: 87.14 (-0.08), GM: 32.07 (-0.08), LBRDK: 50.58 (-0.05), BRK.B: 145.35 (-0.30), VIAB: 73.73 (+0.25), BRK.A: 217,863.00 (-681.92), MA: 84.39 (+0.11)

Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 3:40AM CST

MDLZ: 38.90 (-0.20), DNOW: 27.60 (+0.07), LMCK: 35.38 (-0.24), CHTR: 158.87 (+0.24), MTB: 123.95 (-0.67), WMT: 84.48 (-0.51), KRFT: 58.39 (+0.02), GHC: 869.88 (+1.88), PCP: 230.81 (-2.08), UPS: 105.47 (-0.17), NOV: 72.48 (+0.99), ESRX: 79.57 (+0.10), COST: 139.52 (-0.49), MA: 84.39 (+0.11), PSX: 77.23 (+1.46), TMK: 53.21 (-0.03), COP: 72.71 (+0.58), WFC: 53.27 (-0.09), MCO: 100.32 (-0.28), LMCA: 35.55 (-0.27), BRK.B: 145.35 (-0.30), BRK.A: 217,863.00 (-681.92), WBC: 103.12 (unch), LBTYK: 44.79 (-0.40), GE: 26.90 (-0.02), XOM: 95.66 (+0.05), SU: 34.75 (+0.65), JNJ: 107.76 (-1.00), T: 35.29 (-0.08), V: 250.65 (+0.79), LBTYA: 45.84 (-0.44), IBM: 160.09 (-1.34), DTV: 87.14 (-0.08), SNY: 46.68 (-1.41), BK: 39.75 (-0.04), KO: 44.27 (+0.05), CBI: 55.02 (+0.62), AXP: 90.49 (-0.01), LEE: 3.20 (+0.02), VRSN: 59.52 (+0.14), GS: 188.91 (-0.28), DVA: 74.91 (-0.21), VRSK: 62.13 (-0.08), MEG: 14.62 (+0.09), USB: 43.78 (-0.11), USG: 28.64 (+0.56), GM: 32.07 (-0.08), PG: 88.70 (-0.03), VIAB: 73.73 (+0.25), VZ: 50.21 (-0.28)

Express Scripts Sued in Scheme to Deny Pharmacy Payments for Compound Pharmaceuticals, according to Quadrino Law Group and The Simon Law Firm
Business Wire - Tue Nov 18, 12:53PM CST
Three pharmacies have sued Express Scripts, Inc. for violations of federal regulations in a scheme to deny payments for compound pharmaceuticals. The suit alleges that thousands of patients are being impacted by the scheme, according to Quadrino Law Group and The Simon Law Firm.
ESRX: 79.57 (+0.10)

Look for Shares of Express Scripts to Potentially Pullback after Yesterday's 1.54% Rise
Comtex SmarTrend(R) - Mon Nov 17, 4:44PM CST
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $77.87 to a high of $79.12. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $78.22 on volume of 3.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ESRX: 79.57 (+0.10)

Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Express Scripts Is Up 4.6% (ESRX)
Comtex SmarTrend(R) - Mon Nov 17, 4:06PM CST
When Express Scripts (NASDAQ:ESRX) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.29 on sales of $24.9 billion. Express Scripts actually reported earnings of $1.29 per share on sales of $25.8 billion, matching EPS estimates and beating revenue estimates by $880.0 million. Shares of Express Scripts have climbed from $74.41 to $77.87, representing a gain of 4.6% since the company reported earnings 20 days ago.
ESRX: 79.57 (+0.10)

Berkshire Likes Express Scripts- And So Do We
Morningstar - at Seeking Alpha - Mon Nov 17, 2:13PM CST
By Greggory Warren, CFA While wide-moat Berkshire Hathaway's (NYSE: BRK.B ) third-quarter 13-F filing was overshadowed this week by the firm's announcement that it would be exchanging its 52.8 million share stake in Procter & Gamble (NYSE: PG...
ESRX: 79.57 (+0.10), BRK.B: 145.35 (-0.30), BRK.A: 217,863.00 (-681.92)

Option Traders Bet on These Stocks to Break Out to New Highs
at The Street - Mon Nov 17, 4:45AM CST
An interesting trend emerged in the option market last week as traders bet on stocks to break out to new highs.
SPLS: 14.00 (+0.08), ESRX: 79.57 (+0.10), DNKN: 47.15 (+0.12), LGF: 34.77 (+0.24), AMAT: 22.64 (+0.05), RHT: 63.00 (+0.06), EMC: 30.10 (+0.17), NTAP: 42.01 (+0.20)

Warren Buffett Buys Express Scripts, But You Should Not
Stock Market Sherpa - at Seeking Alpha - Sat Nov 15, 8:55PM CST

ESRX: 79.57 (+0.10)

Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sat Nov 15, 10:45AM CST

KMI: 41.03 (+0.09), VRX: 142.84 (+0.37), HAL: 48.99 (+0.56), KMP: 100.21 (+0.45), BAC: 16.99 (-0.07), TDW: 37.53 (+0.34), VPRT: 67.60 (+0.80), ORCL: 40.97 (+0.05), PRI: 51.55 (+0.71), EPB: 43.18 (+0.26), ESRX: 79.57 (+0.10), EQIX: 224.11 (-1.57), JPM: 60.11 (-0.49), KMR: 101.35 (+0.34), MSFT: 48.14 (-0.08), CMCSA: 54.34 (-0.04), SCHW: 28.31 (-0.21)

Warren Buffett’s Berkshire Hathaway Sells Stake in John Deere and Buys More DirecTV Stock
Patrick Morris, The Motley Fool - Motley Fool - Sat Nov 15, 7:11AM CST
After the market closed today Warren Buffett's Berkshire Hathaway disclosed its latest stock holdings as of September 30, 2014 with the SEC. While the value of its portfolio was unchanged at $108 billion relative to the end of June and it...
ESRX: 79.57 (+0.10), CHTR: 158.97 (+0.34), DTV: 87.14 (-0.08), DE: 85.56 (-0.77), COP: 72.71 (+0.58)

Berkshire ups GM stake, exits Deere, buys into Express Scripts
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:28PM CST

ESRX: 79.57 (+0.10), DE: 85.56 (-0.77), GM: 32.07 (-0.08), BRK.B: 145.35 (-0.30), BRK.A: 217,863.00 (-681.92)

Scour Mutual Fund Special Sections For Great Ideas
at Investor's Business Daily - Wed Nov 12, 3:59PM CST
Institutional sponsorship is a key factor to check when researching stocks to buy. Why? Without demand from mutual funds, hedge funds and other big investors, which account for most of the market's daily activity, a stock cannot keep advancing....
GPRO: 74.61 (-4.48), ESRX: 79.57 (+0.10), WY: 34.21 (+0.01), MA: 84.39 (+0.11)

Express Scripts Earnings In Retrospect: Up 4.6% in the Last 13 Days (ESRX)
Comtex SmarTrend(R) - Mon Nov 10, 1:30PM CST
A week ago on October 28th, 2014 Express Scripts (NASDAQ:ESRX) reported earnings and analysts, on average, expected earnings of $1.29 on sales of $24.9 billion. Express Scripts actually reported earnings of $1.29 per share on sales of $25.8 billion, matching EPS estimates and beating revenue estimates by $880.0 million. Shares of Express Scripts have climbed from $74.41 to $77.87, representing a gain of 4.6% since the company reported earnings 13 days ago.
ESRX: 79.57 (+0.10)

Is CVS Health's "Tobacco-Tax" Brilliant or Stupid?
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 8:44AM CST
Source: CVS Health Supporters are heralding CVS Health 's decision to create narrow pharmacy networks that penalize tobacco users as a brilliant move, but detractors think it may alienate customers. Both sides have valid arguments, but I...
ESRX: 79.57 (+0.10), CTRX: 49.16 (-0.22), MCK: 205.55 (-0.72), CVS: 89.44 (-0.15), WAG: 67.79 (unch), RAD: 5.56 (+0.04)

3 Things That Can Keep the Wind in Catamaran Corp.'s Sails
Keith Speights, The Motley Fool - Motley Fool - Sat Nov 08, 8:00AM CST
It's been a relatively rough year for Catamaran Corporation so far. Just a couple of weeks ago, the pharmacy benefits manager's stock was down more than 10% and even farther away from the highs seen in 2013. After a strong third-quarter earnings...
CI: 101.94 (-0.69), ESRX: 79.57 (+0.10), CTRX: 49.16 (-0.22), CVS: 89.44 (-0.15)

Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry.  In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 107.76 (-1.00), ESRX: 79.57 (+0.10), GILD: 102.20 (-0.14), ABBV: 65.24 (-0.26), BMY: 58.50 (-0.31), ENTA: 43.96 (+0.06)

Quarterly Financial Results, Study Results, and Appointments - Research Reports on Covidien, Community Health, Express Scripts, Caterpillar and Boeing
PR Newswire - Fri Nov 07, 7:35AM CST
Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Community Health Systems, Inc. (NYSE: CYH), Express Scripts Holding Company (NASDAQ: ESRX), Caterpillar Inc. (NYSE: CAT) and The Boeing Company (NYSE: BA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7772-100free.
ESRX: 79.57 (+0.10), CYH: 46.79 (-0.66), COV: 96.94 (-0.56), CAT: 101.21 (-0.09), BA: 131.82 (+0.21)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Schouw & Co.'s Share Buy-Back Strategy for 2025

Updated Category News Views 153

Overview of Schouw & Co.'s Share Buy-Back Program Schouw & Co. has launched an exciting share buy-back initiative, aiming to enhance shareholder value significantly. This program began on May 5, 2025, and is designed to repurchase shares totaling up to DKK 120 million. This investment runs until December 31, 2025, reflecting the company's commitment to its shareholders....

Continue Reading
Schneider National Plans to Reveal Q3 2024 Earnings Soon

Updated Category News Views 45

Schneider National to Report Third Quarter 2024 Earnings Schneider National, Inc. (NYSE: SNDR), a leader in transportation and logistics services, has announced that it will release its third quarter 2024 earnings report on a future date, ahead of the market opening. This announcement is significant as it highlights the company’s continued focus on financial...

Continue Reading
A Closer Look at BioAge Labs: Legal Challenges Ahead

Updated Category News Views 206

Understanding the Legal Landscape of BioAge Labs Investors in BioAge Labs, Inc. have faced new uncertainties as the clinical-stage biopharmaceutical company becomes entangled in legal challenges. As the firm moves forward in its mission to develop innovative therapies aimed at combating metabolic diseases, significant developments have emerged that every investor should...

Continue Reading
Celebrating the Fusion of Science and Cinema at Starmus 2025

Updated Category News Views 202

Fusion of Science and Cinema at Starmus Festival The Starmus Festival is a unique event that intertwines science and art, culminating in extraordinary dialogues and presentations. Recently, renowned director Christopher Nolan was awarded the prestigious Stephen Hawking Medal for Science Communication during this remarkable celebration. This accolade is not just an honor...

Continue Reading
Millicom Takes Steps to Enhance Transparency in Holdings

Updated Category News Views 82

Millicom Takes Steps to Enhance Transparency in Holdings Millicom International Cellular S.A., commonly recognized as Tigo, is making significant strides in open communication and compliance by submitting regulatory notifications regarding major shareholder holdings. This initiative reinforces their commitment to transparency and regulatory excellence in the ever-evolving...

Continue Reading